Athyglisbrestur

Athyglisbrestur er taugaröskun sem veldur einbeitingarskorti ýmist með ofvirkni (og kallast þá ADHD)[a] eða án (ADD).[b] Auk einbeitingarskorts einkennis athyglisbrestur með ofvirkni oft af hvatvísi og sumir eiga erfitt með að hafa stjórn á eigin tilfinningum.[1][2][3][4] Greining byggist á því hvort einbeitingarskortur hafi verið til staðar í meira en hálft ár, valdi viðkomandi vandræðum t.d. heima eða í skóla, og hvort einkenni hafi komið fram í barnæsku.[5][6]

Meðferð inniheldur atferlismeðferð og lyf á við örvandi lyfið metýlfenídat (Rítalín).[7]

Talið er að athyglisbrestur sé tengdur brenglun í boðefnakerfi heilans, þá sérstaklega heilaboðefnunum dópamíni og noradrenalíni.

NeðanmálsgreinarBreyta

  1. Á ensku: „attention deficit hyperactivity disorder“
  2. Á ensku: „attention deficit disorder“

TilvísanirBreyta

  1. Faraone SV, Rostain AL, Blader J, Busch B, Childress AC, Connor DF, Newcorn JH (February 2019). „Practitioner Review: Emotional dysregulation in attention-deficit/hyperactivity disorder - implications for clinical recognition and intervention“. Journal of Child Psychology and Psychiatry, and Allied Disciplines. 60 (2): 133–150. doi:10.1111/jcpp.12899. PMID 29624671.
  2. Tenenbaum RB, Musser ED, Morris S, Ward AR, Raiker JS, Coles EK, Pelham WE (April 2019). „Response Inhibition, Response Execution, and Emotion Regulation among Children with Attention-Deficit/Hyperactivity Disorder“. Journal of Abnormal Child Psychology. 47 (4): 589–603. doi:10.1007/s10802-018-0466-y. PMC 6377355. PMID 30112596.
  3. Lenzi F, Cortese S, Harris J, Masi G (January 2018). „Pharmacotherapy of emotional dysregulation in adults with ADHD: A systematic review and meta-analysis“. Neuroscience and Biobehavioral Reviews. 84: 359–367. doi:10.1016/j.neubiorev.2017.08.010. PMID 28837827.
  4. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (5th. útgáfa). Arlington: American Psychiatric Publishing. bls. 59–65. ISBN 978-0-89042-555-8.
  5. „Symptoms and Diagnosis“. Attention-Deficit / Hyperactivity Disorder (ADHD). Division of Human Development, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. 29. september 2014. Afrit af upprunalegu geymt þann 7. nóvember 2014. Sótt 3. nóvember 2014.
  6. Dulcan, Mina K.; Lake, MaryBeth (2011). „Axis I Disorders Usually First Diagnosed in Infancy, Childhood or Adolescence: Attention-Deficit and Disruptive Behavior Disorders“. Concise Guide to Child and Adolescent Psychiatry (4th illustrated. útgáfa). American Psychiatric Publishing. bls. 34. ISBN 978-1-58562-416-4 – gegnum Google Books.
  7. Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, Moreira-Maia CR, Magnusson FL, Holmskov M, Gerner T, Skoog M, Rosendal S, Groth C, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Håkonsen SJ, Aagaard L, Simonsen E, Gluud C (May 2018). „Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies“. The Cochrane Database of Systematic Reviews. 5: CD012069. doi:10.1002/14651858.CD012069.pub2. PMC 6494554. PMID 29744873.

TenglarBreyta


   Þessi heilsugrein er stubbur. Þú getur hjálpað til með því að bæta við greinina.